MESO FY 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-26.5% YoY

Gross Profit

-$47M-632.2% margin

Operating Income

-$69M-923.7% margin

Net Income

-$82M-1091.7% margin

EPS (Diluted)

$-0.98

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$64M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$669M

Total Liabilities

$168M

Stockholders' Equity

$502M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$10M	-26.5%
Gross Profit	-$47M	-$53M	+11.1%
Operating Income	-$69M	-$81M	+14.0%
Net Income	-$82M	-$91M	+10.4%